Purdue Execs’ Exclusion Stands But Court Tells HHS To Justify 12-Year Term
This article was originally published in The Pink Sheet Daily
Executive Summary
The question now is whether HSS Secretary Sebelius will provide a rationale to continue the 12-year exclusion or reduce the length of the exclusion; appeals court upholds HHS’s authority to exclude three former Purdue Pharma executives from federal health care programs, but notes the length of the sanction departs from similar cases.
You may also be interested in...
Former Indivior CMO Challenges HHS’ Exclusion For ‘Responsible Corporate Officer’ Misdemeanor
Former chief medical officer’s conviction for misbranding Suboxone does not warrant mandatory exclusion from healthcare programs, complaint argues. It says individuals in similar situations, specifically former Purdue execs, were subject to permissive exclusion.
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.
Still Guilty: Three Former Purdue Execs Lose Fight To Overturn Their Exclusion From Gov't Programs
"As with plaintiffs' repeated attempts to characterize themselves as innocent third parties to Purdue's misbranding, the court finds plaintiffs' arguments with respect to financial loss reflective of a fundamental misconception of their own plea agreements," the ruling states.